BRIDGE HCVBuilding Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Collier MG, et al. Am J Public Health. 2015;105(2):302–303.
Mehta SH, Thomas DL. J Hepatol. 2016;65(1):5-6.
Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.
McLellan AT, et al. JAMA. 2000;284(13):1689-1695.
Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials.
Grebely J, et al. Clin Infect Dis. 2016;63(11):1405-1411.
Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials.
Grebely J, et al. Clin Infect Dis. 2016;63(11):1479-1481.
Elbasvir/grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial.
Dore GJ, et al. Ann Intern Med. 2016;165(9):625-634.
Wurcel AG, et al. Clin Infect Dis. 2015;61(12):1840-1849.
Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals.
Rich ZC, et al. BMC Public Health. 2016;16:994.
Kim AY, Page K. J Infect Dis. 2013;208(12):1929-1931.
Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
Islam N, et al. Lancet Gastroenterol Hepatol. 2017;2(3):200-210.
Medical and behavioral approaches to engage people who inject drugs into care for hepatitis C virus infection.
Gonzalez SA, et al. Addict Disord Their Treat. 2017;16(2 suppl 1):S1-S23.
U.S. Department of Health and Human Services, 2017.
Outcomes from a large 10-year hepatitis C treatment programme in people who inject drugs: no effect of recent or former injecting drug use on treatment adherence or therapeutic response.
Elsherif O, et al. PLoS One. 2017;12(6):e0178398.
SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy.
Grebely J, et al. European Association for the Study of the Liver. The International Liver Congress™ − EASL 2017. April 19-23, 2017; Amsterdam, The Netherlands.
Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study.
Bruneau J, et al. Clin Infect Dis. 2014;58(6):755-761.
Wilson DP, et al. Int J Drug Policy. 2015:26(suppl 1):S5-S11.
Falade-Nwulia O, Sulkowski M. J Hepatol. 2017;66(2): 267-269.
Younossi Z, et al. Am J Manag Care. 2017;23(2):107-112.
Grebely J, Dore GL. Clin Liver Dis. 2017;9(4):77-80.
Action and Advocacy
EDUCATION AND TRAINING
Gulati R, et al. Clin Liver Dis. 2018;11(2):48-51.
The Hepatitis Education Project provides support, education, advocacy, and direct services for people affected by hepatitis, and works to raise hepatitis awareness among patients, medical providers, and the general public.
The National Hepatitis Corrections Network (NHCN) supports a public health approach to hepatitis education, prevention, testing, and treatment in prisons and jails.
Project ECHO is a collaborative, telecommunications-based model of medical education and care management designed to train primary care clinicians to provide specialty care in rural and underserved areas.
Substance Abuse and Mental Health Services Administration (SAMHSA), 2018.
PUBLIC POLICY: EXPANSION OF ACCESS TO CARE
Akiyama MJ, et al. Am J Public Health. 2018;108(5):607-608.
Center on Budget and Policy Priorities, 2019.
Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) and National Viral Hepatitis Roundtable (NVHR).
Together, CHLPI and NVHR continue to play a pivotal role in removing Medicaid restrictions on HCV treatment. An interactive map allows you to see each state’s Medicaid restrictions. Last updated November 2018.
Economic and public health impacts of policies restricting access to hepatitis C treatment for Medicaid patients.
Chidi AP, et al. Value Health. 2016;19(4):326-334.
Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial.
Kattakuzhy S, et al. Ann Intern Med. 2017;167(5):311-318.
The National Viral Hepatitis Roundtable (NVHR) is a coalition working together to eliminate hepatitis B and C in the United States.
CLINIC OPERATIONS: TOOLS AND RESOURCES
National Viral Hepatitis Roundtable: Online Resources.
This page supplies information regarding coding and billing for hepatitis services.
This page provides a variety of resources for implementing clinical decision support tools and/or HCV-testing prompts in electronic medical records (EMRs).
Resources for Training Primary Care Providers and Other Health Care Workers About HCV Screening and Linkage to Care.
This page furnishes or links to a variety of resources, including CARE-NAVIGATION TOOLS:
- HCV Treatment and Insurance Protocol: Prior Authorization Process
- Medicare Learning Network (MLN) Matters: Submitting Claims to Medicare for HCV Screening
- Sample Appeals Letters (Templates)
NASEN provides a directory of syringe exchange programs that can be located by zip code, landmark, city, or state.
SAMHSA provides confidential and anonymous information on substance abuse and mental health treatment facilities throughout the United States and its territories.
SAMHSA provides numerous links to nonprofit associations, federal agencies, and patient groups that offer support for providers of medication-assisted treatment (MAT), as well as patients and families.
Have You Ever Injected Drugs? What You Need to Know About Hepatitis C
Current or past injection drug use puts you at high risk for hepatitis C infection. But there is good news for those who are infected: New treatments are available that cure most people—even injection drug users. This video provides important information on your risk for Hepatitis C, getting tested, and—if you're infected—getting cured.
Building Bridges to Reach People Who Inject Drugs with the Goal to Eliminate HCV
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care